Earnings Update: Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

It's been a good week for Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) shareholders, because the company has just released its latest quarterly results, and the shares gained 4.2% to €7.52. It was a credible result overall, with revenues of €63m and statutory earnings per share of €0.32 both in line with analyst estimates, showing that Fine Foods & Pharmaceuticals N.T.M is executing in line with expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Our free stock report includes 1 warning sign investors should be aware of before investing in Fine Foods & Pharmaceuticals N.T.M. Read for free now.

Taking into account the latest results, the current consensus from Fine Foods & Pharmaceuticals N.T.M's two analysts is for revenues of €263.0m in 2025. This would reflect a decent 8.8% increase on its revenue over the past 12 months. Before this earnings report, the analysts had been forecasting revenues of €269.1m and earnings per share (EPS) of €0.50 in 2025. So we can see that while the consensus made a minor downgrade to revenue estimates, it no longer provides an earnings per share estimate. This suggests that the market is now more focused on revenue after the latest result.

Check out our latest analysis for Fine Foods & Pharmaceuticals N.T.M

We'd also point out that thatthe analysts have made no major changes to their price target of €11.73.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Fine Foods & Pharmaceuticals N.T.M's rate of growth is expected to accelerate meaningfully, with the forecast 12% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 9.4% p.a. over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 11% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Fine Foods & Pharmaceuticals N.T.M is expected to grow at about the same rate as the wider industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their revenue estimates for next year. They also downgraded their revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider industry. The consensus price target held steady at €11.73, with the latest estimates not enough to have an impact on their price targets.

At least one of Fine Foods & Pharmaceuticals N.T.M's two analysts has provided estimates out to 2027, which can be seen for free on our platform here.

And what about risks? Every company has them, and we've spotted 1 warning sign for Fine Foods & Pharmaceuticals N.T.M you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.